Starting signal sounded: analytica 2012 to offer Early Bird discount

The starting signal has sounded for analytica 2012 in Munich. Application forms for the 23rd International Trade Fair for Laboratory Technology, Analysis and Biotechnology are available to interested companies. Also, a new offer is being introduced this year: For the first time ever, companies that register by January 31, 2011 will receive a five-percent Early Bird discount on selected stand space. Stand-space allocation for analytica 2012 was also moved forward considerably, i.e. to March 15, 2011.

"Preparations for analytica 2012 are already moving ahead at full speed. New application forms are now available," explains Susanne Grödl, Exhibition Director for analytica at Messe München. "As a result, things are moving along much earlier than in previous years, and we can offer our exhibitors an additional incentive: an Early Bird discount of five percent."

The discount applies to all stand space booked between September 1, 2010 and January 31, 2011, regardless of stand size and type (corner, row or island stand). The offer that is even worthwhile for smaller stands.

"The objective of this campaign is to give exhibitors an incentive to book their stand space early," adds Grödl. "After all, earlier registration allows us to move the entire planning process including visitor advertising considerably forward in time - which is something that exhibitors ultimately profit from."

Companies that do not automatically receive their application forms for the 2012 fair can download them directly at www.analytica.de/en/2012.

Most Popular Now

BioMotiv and Bristol-Myers Squibb announce the lau…

BioMotiv, a mission-driven drug development accelerator associated with The Harrington Project for discovery and development, that advances breakthrough discoveries from ...

CEPI and GSK announce collaboration to strengthen …

CEPI, the Coalition for Epidemic Preparedness Innovations, and GSK announced a new collaboration aimed at helping the global effort to develop a vaccine for the 2019-nCoV...

Sandoz completes acquisition of Aspen's Japanese o…

Sandoz today announced that it has successfully completed the acquisition of the Japanese business of Aspen Global Incorporated (AGI), a wholly owned subsidiary of Aspen ...

Roche reports very strong results in 2019

In 2019, Group sales rose 9% to CHF 61.5 billion and core EPS grew 13%, ahead of sales. The core operating profit increased 11%, reflecting the strong underlying business...

Sanofi brain-penetrant BTK inhibitor meets primary…

The Sanofi Phase 2b study evaluating its investigational BTK (Bruton's tyrosine kinase) inhibitor (SAR442168), an oral, brain-penetrant, selective small molecule, achieve...

Sanofi completes acquisition of Synthorx, Inc.

Sanofi announced the successful completion of its acquisition of Synthorx, Inc. ("Synthorx") for $68 per share in cash. "The acquisition of Synthorx perfectly aligns w...

Merck donates one billionth praziquantel tablet

Merck, a leading science and technology company, today announced that it has already donated 1 billion tablets of praziquantel, the standard medication for the treatment ...

WHO, China leaders discuss next steps in battle ag…

The Director-General of the World Health Organization (WHO), Dr Tedros Adhanom Ghebreyesus, met President Xi Jinping of the People's Republic of China in Beijing. They sh...

Poliovirus therapy shows potential as cancer vacci…

A modified form of poliovirus, pioneered at Duke Cancer Institute as a therapy for glioblastoma brain tumors, appears in laboratory studies to also have applicability for...

AstraZeneca divests rights to established hyperten…

AstraZeneca has agreed to sell the global commercial rights to Inderal (propranolol), Tenormin (atenolol), Tenoretic (atenolol, chlorthalidone fixed-dose combination), Ze...

Botanical drug is shown to help patients with head…

In a UCLA-led phase I clinical trial, a new plant-based drug called APG-157 showed signs of helping patients fight oral and oropharyngeal cancers. These cancers are locat...

FDA approves first drug for treatment of peanut al…

Today the U.S. Food and Drug Administration approved Palforzia [Peanut (Arachis hypogaea) Allergen Powder-dnfp] to mitigate allergic reactions, including anaphylaxis, tha...